Outlook Therapeutics, Inc. (OTLK) — SEC Filings
Outlook Therapeutics, Inc. (OTLK) — 50 SEC filings. Latest: 424B5 (Mar 23, 2026). Includes 32 8-K, 5 10-Q, 3 SC 13G.
View Outlook Therapeutics, Inc. on SEC EDGAR
Overview
Outlook Therapeutics, Inc. (OTLK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Mar 23, 2026: Outlook Therapeutics, Inc. filed a 424B5 prospectus on March 23, 2026, related to its previously filed registration statement 333-278340. This filing is a standard procedure for offering securities, indicating the company is likely preparing to raise capital. For investors, this matters because it s
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Outlook Therapeutics, Inc. is neutral.
Filing Type Overview
Outlook Therapeutics, Inc. (OTLK) has filed 1 424B5, 2 10-K, 32 8-K, 5 10-Q, 2 DEF 14A, 1 10-K/A, 2 SC 13G/A, 2 SC 13D/A, 3 SC 13G with the SEC between Mar 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of OTLK's 44 recent filings, 5 were flagged as high-risk, 32 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Disclosed |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Paul E. Chaney
- Dr. Paul Ashton
- Ms. Karen Smith
- Dr. Lawrence M. Feinberg
- Ghiath M. Sukhtian
Industry Context
The anti-VEGF retina market is a substantial and growing sector, driven by the increasing prevalence of age-related macular degeneration and diabetic retinopathy. While several approved therapies exist, a significant portion of the market, particularly in the US and Europe, is served by off-label use of bevacizumab due to its efficacy and lower cost. Companies like Outlook Therapeutics are seeking to capture this segment with approved, ophthalmic formulations of bevacizumab, aiming to offer a more standardized and potentially safer alternative to repackaged drugs.
Top Tags
asset-sale (9) · financials (8) · financing (7) · capital-raise (4) · filing (4) · 8-K (4) · biotech (4) · corporate-event (3) · sec-filing (3) · executive-appointment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| aggregate market value of common stock held by non-affiliates | $26.9 million | as of March 31, 2025, indicating a relatively small market capitalization |
| shares of common stock outstanding | 64,114,399 | as of December 16, 2025 |
| estimated total anti-VEGF retina market in Europe | $3.6 billion | represents a significant market opportunity for ONS-5010/LYTENAVA |
| estimated total anti-VEGF retina market in the United States | $8.5 billion | represents a critical, yet currently inaccessible, market for ONS-5010/LYTENAVA |
| estimated global market for anti-VEGF retina | $16 billion | overall market size for ONS-5010/LYTENAVA |
| annual off-label bevacizumab injections in Europe | 2.8 million | highlights the existing demand ONS-5010/LYTENAVA aims to capture |
| annual off-label bevacizumab injections in the United States | 2.7 million | underscores the potential US market if approved |
| of US physicians prefer off-label repackaged bevacizumab as first-line product | 55% | indicates strong market preference ONS-5010/LYTENAVA could address with approval |
| of total US anti-VEGF market is off-label bevacizumab | 34% | demonstrates the significant segment ONS-5010/LYTENAVA could penetrate |
| Commission File Number | 001-37759 | SEC file identifier for Outlook Therapeutics, Inc. |
| IRS Employer Identification No. | 38-3982704 | Tax identification number for Outlook Therapeutics, Inc. |
| Net Revenues | $1,505,322 | Generated for the three and nine months ended June 30, 2025, from zero in prior periods, due to LYTENAVA launch. |
| Net Loss (3 months) | $20,152,502 | Reported for the three months ended June 30, 2025, compared to net income of $44,409,187 in the prior year. |
| Net Loss (9 months) | $49,132,094 | Reported for the nine months ended June 30, 2025, compared to a net loss of $81,057,995 in the prior year. |
| Accumulated Deficit | $592,416,994 | As of June 30, 2025, indicating significant historical losses and contributing to going concern doubt. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Outlook Therapeutics, Inc. (OTLK)?
Outlook Therapeutics, Inc. has 50 recent SEC filings from Mar 2024 to Mar 2026, including 32 8-K, 5 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OTLK filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Outlook Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Outlook Therapeutics, Inc. (OTLK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Outlook Therapeutics, Inc.?
Key financial highlights from Outlook Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OTLK?
The investment thesis for OTLK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Outlook Therapeutics, Inc.?
Key executives identified across Outlook Therapeutics, Inc.'s filings include Dr. Paul E. Chaney, Dr. Paul Ashton, Ms. Karen Smith, Dr. Lawrence M. Feinberg, Ghiath M. Sukhtian.
What are the main risk factors for Outlook Therapeutics, Inc. stock?
Of OTLK's 44 assessed filings, 5 were flagged high-risk, 32 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Outlook Therapeutics, Inc.?
Forward guidance and predictions for Outlook Therapeutics, Inc. are extracted from SEC filings as they are enriched.